IDOL

Non-small cell lung cancer (NSCLC), the most common form of lung cancer at approximately 85%, shows a high tendency to develop resistance to chemotherapeutic agents, resulting in the absence of desired treatment effects, a high frequency of recurrences, and a high mortality rate of affected patients. For use in routine clinical diagnostics, the partners HS Analysis and NMI are therefore developing a novel multiplexed and AI-assisted diagnostic test for quantitative determination of the presence of drug resistance in the case of NSCLC. The use and the obtained results of the new test enable successful concepts of cancer therapy, e.g. adjuvant treatment to mitigate drug resistance or targeted immunotherapeutic procedures, and thus a significantly increased treatment success after diagnosis of NSCLC in the future.